Related Experiment Video

Updated: May 2, 2026

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases
06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

856

Expression of set is downregulated by rapamycin in human colorectal cancer cells

Xiaoxia Wen1, Yao Chen1

  • 1Department of Anatomy, College of Basic and Forensic Medicine, Sichuan University, Chengdu, Sichuan 610041, P.R. China.

Biomedical Reports
|March 21, 2014
PubMed

Insights

Rapamycin treatment significantly downregulates the SET gene's mRNA and protein expression in human colorectal cancer cells. This suggests the mammalian target of rapamycin pathway influences tumorigenesis via SET gene regulation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Colorectal adenocarcinoma is a significant global health concern.
  • The SET gene's role in colorectal cancer progression is not fully understood.
  • Rapamycin is an immunosuppressant drug with potential anti-cancer properties.

Purpose of the Study:

  • To investigate the mechanism by which rapamycin affects SET gene expression in human colorectal adenocarcinoma cells.
  • To determine if rapamycin influences SET gene mRNA and protein levels.
  • To explore the potential role of the mammalian target of rapamycin (mTOR) signaling pathway in regulating SET gene expression.

Main Methods:

  • Utilized SW480 and LoVo human colon carcinoma cell lines.
  • Administered rapamycin treatment to cell cultures.
  • Quantified SET gene mRNA levels using quantitative polymerase chain reaction (qPCR).
  • Assessed SET gene protein expression via western blot analysis.

Main Results:

  • Rapamycin treatment led to a significant decrease in SET gene mRNA expression in both cell lines.
  • Rapamycin treatment resulted in a significant reduction of SET gene protein levels.
  • SET gene expression is downregulated by rapamycin in human colorectal adenocarcinoma cells.

Conclusions:

  • Rapamycin downregulates SET gene expression in human colorectal adenocarcinoma cells.
  • The mammalian target of rapamycin (mTOR) signaling pathway may regulate the SET gene.
  • The mTOR-SET gene axis could be a potential therapeutic target in colorectal cancer tumorigenesis.
Keywords:
human colorectal adenocarcinomamammalian target of rapamycinrapamycinset

More Related Videos

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin10:21

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

Published on: September 12, 2019

7.9K
A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

16.3K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.1K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.0K